Consensus MannKind Corporation

Stocks

MNKD

US56400P7069

Biotechnology & Medical Research

Delayed Nasdaq 00:00:00 05/09/2026 +04			5-day change	1st Jan Change
4.060 ^USD	+2.53%		+2.78%	-28.40%

08-06	MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says	MT
08-06	MannKind Corporation, Q2 2026 Earnings Call, Aug 05, 2026

Evolution of the Average Target: MannKind Corporation

Evolution of the Target Price: MannKind Corporation

Changes in Analyst Recommendations: MannKind Corporation

20a6c5.hdilc7HFQtBdIGJKvZAUIirVPBE4xiFm-vdu3fZVw_8.6ZPHNNqQMugqUSMg6uRmdEaXVlgPghMei4Rfmo8ggLy3rfok-fEEiTJ3FQ~80324764ad9eec0156476ab28b9af22a

Analysts' recommendations: MannKind Corporation

08-06	MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says	MT
07-30	MannKind Top-Line Data From Phase 1b INFLO-1 Study 'Positive,' Wedbush Says	MT
07-24	MannKind's Furoscix Auto-Injector Approval, Launch Could Provide Strong Upside to 2026 Revenue Expectation, Wedbush Says	MT
03-05	Wedbush Adjusts Price Target on MannKind to $8 From $10, Maintains Outperform Rating	MT
02-27	RBC Downgrades MannKind to Sector Perform From Outperform, Cuts Price Target to $3.50 From $7.50	MT
11-11	RBC Lowers Price Target on MannKind to $7.50 From $8, Keeps Outperform Rating	MT
11-11	Wedbush Cuts Price Target on MannKind to $10 From $11, Keeps Outperform Rating	MT
13/10/25	MannKind's Supplemental BLA for Diabetes Treatment Afrezza Facing 'Limited Regulatory Risk,' Wedbush Says	MT
13/10/25	MannKind announces US FDA accepts for review its sBLA for inhaled insulin	RE
05/09/25	Oppenheimer Adjusts MannKind Price Target to $15 From $12, Maintains Outperform Rating	MT
26/08/25	RBC Raises Price Target on MannKind to $8 From $7, Keeps Outperform Rating	MT
07/08/25	RBC Cuts Price Target on MannKind to $7 From $8, Keeps Outperform Rating	MT
06/08/25	Biotech firm MannKind's Q2 revenue rises 6%	RE
23/07/25	RBC Cuts Price Target on MannKind to $8 From $10, Keeps Outperform Rating	MT
10/04/25	Mizuho Initiates MannKind at Outperform With $12 Price Target	MT
10/02/25	Wedbush Initiates MannKind at Outperform With $11 Price Target	MT
20/12/24	MannKind Shares Rise After Wells Fargo Begins Coverage	MT
20/12/24	Wells Fargo Initiates Coverage on MannKind With Overweight Rating, $9 Price Target	MT
19/12/24	RBC Upgrades MannKind to Outperform From Sector Perform, Raises Price Target to $10 From $7	MT
14/11/24	Tudor Pickering Holt Downgrades MannKind to Hold From Buy, Adjusts Price Target to $5.50 From $7	MT
08/11/24	RBC Capital Adjusts Price Target on MannKind to $7 From $5, Maintains Sector Perform Rating	MT
28/08/24	Oppenheimer Adjusts MannKind Price Target to $12 From $10, Maintains Outperform Rating	MT
14/11/23	Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating	MT
10/10/23	Wedbush Initiates MannKind at Outperform With $10 PT; Says Orphan Lung Pipeline Presents Potential for Real Future Value-Creation, Optionality	MT
14/08/23	HC Wainwright Adjusts Price Target on MannKind to $7.50 From $7, Keeps Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MANNKIND CORPORATION					+96.27%
	WUXI APPTEC CO., LTD.					+21.09%
	ARGENX SE					+11.95%
	INSMED INCORPORATED					+58.51%
	BIONTECH SE					+15.94%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.61%
	GENMAB A/S					+12.11%
	PHARMAESSENTIA CORPORATION					+6.66%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+26.36%
	EXELIXIS, INC.					-9.02%
	Average					+25.65%
	Weighted average by Cap.					+19.30%